Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance

Klebsiella_pneumoniae_bacteria_with_a_human_neutrophil_(red)_containing_ingested_Klebsiella_pneumoniae_(purple)

Source: NIAID

The Novo Nordisk Foundation and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) have announced the renewal of their partnership to accelerate the development of an integrated portfolio of innovative products to address bacterial infections and antimicrobial resistance (AMR).

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE